Novel cardiac myosin activators for acute heart failure.
Heart failure remains a leading cause of hospitalisation and death. Treatment of acute heart failure has not improved as rapidly as treatment for chronic heart failure. There are three classes of inotropic agents that are in use at present: the catecholamines, phosphodiesterase inhibitors and calcium sensitisers. Cardiac-specific myosin ATPase activators are a novel class of agents designed to improve myocardial contractility by accelerating the productive phosphate-release step of the crossbridge cycle. This article reviews the mechanism of action of myosin ATPase activators, the results of preclinical and Phase I studies and their potential role in the management of heart failure.
Bragadeesh
Thanjavur K M
TK
Castle Hill Hospital, Department of Academic Cardiology, Cottingham, Kingston-Upon-Hull, HU16 5JQ, UK. bragadeesh02@gmail.com
Mathur
Gaurav
G
Clark
Andrew L
AL
Cleland
John G F
JG
D000818:Animals; D024722:Cardiac Myosins / Q000502:physiology*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D009200:Myocardial Contraction / Q000502:physiology
D002316:Cardiotonic Agents; D024722:Cardiac Myosins